Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UCB's Keppra Follow-On Briviact Gains FDA Nod For Epileptic Seizures

This article was originally published in The Pink Sheet Daily

Executive Summary

A next-generation version of levetiracetam, brivaracetam could help UCB recapture some revenue it's losing to generic competition for the mature epilepsy drug.

Advertisement

Related Content

UCB Predicts Briviact Sales Of €450m by 2026; Plans New Partnerships
UCB Exercises Tozadenant Option But Asks Biotie To Move It To Phase III
Epilepsy NMEs: A View Of The Playing Field

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079127

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel